Ipilimumab in a Phase II trial of melanoma patients with brain metastases

Por Margolin, Kim
Publicado em 2012

Tumor-infiltrating lymphocytes in melanoma

Por Lee, Sylvia, Margolin, Kim
Publicado em 2012

Cytokines in Cancer Immunotherapy

Por Lee, Sylvia, Margolin, Kim
Publicado em 2011

Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications

Por Grossmann, Kenneth F., Margolin, Kim
Publicado no Ther Adv Med Oncol (2015)

Summary of the primer on tumor immunology and the biological therapy of cancer

Por Li, Yufeng, Liu, Shujuan, Margolin, Kim, Hwu, Patrick
Publicado em 2009

Adoptively transferred melanoma-reactive CTL primed in the presence of IL-21 and transferred with concurrent CTLA4 blockade results in enhanced CTL persistence and tumor regression

Por Yee, Cassian, Chapuis, Aude, Greenberg, Phil, Lai, Ivy, Thompson, John A, Margolin, Kim
Publicado em 2014

CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma

Por Margolin, Kim, Wong, Hing C, Morishima, Chihiro, Hernandez, Liza, Ernstoff, Marc, Rhode, Peter R, Waldmann, Thomas A
Publicado no J Immunother Cancer (2014)

Hemorrhagic collision metastasis in a cerebral arteriovenous malformation

Por Sundarakumar, Dinesh K, Marshall, Desiree A, Keene, C Dirk, Rockhill, Jason K, Margolin, Kim A, Kim, Louis J
Publicado em 2014

29(th) Annual meeting of the Society for Immunotherapy of Cancer (SITC)

Por Hurwitz, Arthur A, Lee, Sylvia, Knox, Susan, Kohrt, Holbrook, Verdeil, Gregory, Romano, Emanuela, Margolin, Kim, Urba, Walter J, Speiser, Daniel E
Publicado no J Immunother Cancer (2015)

Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512

Por Bhatia, Shailender, Moon, James, Margolin, Kim A., Weber, Jeffrey S., Lao, Christopher D., Othus, Megan, Aparicio, Ana M., Ribas, Antoni, Sondak, Vernon K.
Publicado em 2012

Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin

Por Tarhini, Ahmad A., Frankel, Paul, Margolin, Kim A., Christensen, Scott, Ruel, Christopher, Shipe-Spotloe, Janice, Gandara, David R, Chen, Alice, Kirkwood, John M.
Publicado em 2011

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

Por Li, Tianhong, Christensen, Scott D., Frankel, Paul H., Margolin, Kim A., Agarwala, Sanjiv S., Luu, Thehang, Mack, Philip C., Lara, Primo N., Gandara, David R.
Publicado em 2010

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Por Schadendorf, Dirk, Hodi, F. Stephen, Robert, Caroline, Weber, Jeffrey S., Margolin, Kim, Hamid, Omid, Patt, Debra, Chen, Tai-Tsang, Berman, David M., Wolchok, Jedd D.
Publicado no J Clin Oncol (2015)

Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)

Por Margolin, Kim A., Moon, James, Flaherty, Lawrence E., Lao, Christopher D., Akerley, Wallace L., Othus, Megan, Sosman, Jeffrey A., Kirkwood, John M., Sondak, Vernon K.
Publicado em 2012

Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: Clinical outcome and quality of life in long-term survivors

Por Pal, Sumanta K., Yamzon, Jonathan, Sun, Virginia, Carmichael, Courtney, Saikia, Junmi, Ferrell, Betty, Frankel, Paul, Hsu, JoAnn, Twardowski, Przemyslaw, Stein, Cy A., Margolin, Kim
Publicado em 2012

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and...

Por Flaherty, Keith T., Manola, Judith B., Pins, Michael, McDermott, David F., Atkins, Michael B., Dutcher, Janice J., George, Daniel J., Margolin, Kim A., DiPaola, Robert S.
Publicado no J Clin Oncol (2015)

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in pat...

Por Weber, Jeffrey, Grob, Jean-Jaques, Margolin, Kim A, Ascierto, Paolo A, Sznol, Mario, Ott, Patrick A, Lejeune, Chantal, de Pril, Veerle, Ruisi, Mary M, Hodi, F Stephen
Publicado no J Immunother Cancer (2015)

A Phase II Study of RO4929097 Gamma-Secretase Inhibitor in Metastatic Melanoma: SWOG 0933

Por Lee, Sylvia M., Moon, James, Redman, Bruce G., Chidiac, Tarek, Flaherty, Lawrence E., Zha, Yuanyuan, Othus, Megan, Ribas, Antoni, Sondak, Vernon K., Gajewski, Thomas F., Margolin, Kim A.
Publicado no Cancer (2014)

Transferred melanoma-specific CD8(+) T cells persist, mediate tumor regression, and acquire central memory phenotype

Por Chapuis, Aude G., Thompson, John A., Margolin, Kim A., Rodmyre, Rebecca, Lai, Ivy P., Dowdy, Kaye, Farrar, Erik A., Bhatia, Shailender, Sabath, Daniel E., Cao, Jianhong, Li, Yongqing, Yee, Cassian
Publicado em 2012

NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy

Por Hudes, Gary R., Carducci, Michael A., Choueiri, Toni K., Esper, Peg, Jonasch, Eric, Kumar, Rashmi, Margolin, Kim A., Michaelson, M. Dror, Motzer, Robert J., Pili, Roberto, Roethke, Susan, Srinivas, Sandy
Publicado no J Natl Compr Canc Netw (2011)